Again as reported in Fierce Biotech, GSK and Actelion have pulled the development plug on their insomnia drug, almorexant over patient tolerance conerns. This after GSK had signed a deal with Actelion in 2008 for up to $3.25 B in upfronts and milestones.
Almorexant was targeted to treat insomnia and also Alzheimer's and insomnia-related depression (it is likely inducing some of this now!). The drug had been projected by [very] eager analysts to hit peak sales of as much as $6 B annually - that's quite a Mother's little helper.
But now due to safety concerns, instead of putting people to sleep the drug itself will be laid to rest.
Goodnight Gracie.
Posted by Bruce Lehr Jan 28th 2011.
Comments